Option Care Health (NASDAQ:OPCH) stock fell nearly 4% after Goldman Sachs downgraded it from "Buy" to "Neutral" due to concerns about prescription cost pressures. The company faces challenges with key products like Stelara, leading to a lowered price target of $27.